Clinical Trials Browser

Phase 1/2 × Cholangiocarcinoma × Sarcoma × Clear all

Glioblastoma, Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT05732831 2025-11-14

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Recruiting

225 enrolled

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT04742959 2024-04-26

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Phase 1/2 Completed

203 enrolled

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Phase 1/2 Completed

21 enrolled 33 charts

CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma

NCT00041808 2005-06-24

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

Phase 1/2 Completed

20 enrolled

BreastDermatologicGastrointestinalSarcomaThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Gastrointestinal Stromal Tumors

Clinical Trials

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver